This company has been marked as potentially delisted and may not be actively trading. Opiant Pharmaceuticals (OPNT) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Movers From YesterdayOctober 10, 2024 | benzinga.comCNFinance Hldgs (NYSE:CNF) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comHikma Pharmaceuticals PLC ADR (HKMPY)April 18, 2024 | investing.comIonis PharmaceuticalsJanuary 31, 2024 | forbes.comUPDATE 2-US FDA approves Opiant's spray for reversing opioid-related overdosesMay 24, 2023 | msn.comREFILE-US FDA approves Opiant's overdose reversal sprayMay 23, 2023 | msn.comIndivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science PortfolioMarch 3, 2023 | msn.comTrading was temporarily halted for "OPNT" at 07:03 PM with a stated reason of "News pending."March 2, 2023 | marketbeat.comOpiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership, institutions own 33%February 22, 2023 | finance.yahoo.comOpiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCFebruary 7, 2023 | finance.yahoo.comHorizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update)January 26, 2023 | seekingalpha.comOpiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid OverdoseJanuary 19, 2023 | finance.yahoo.comDechra Pharmaceuticals defies cooling pets marketJanuary 14, 2023 | thetimes.co.ukOpiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown InJanuary 13, 2023 | seekingalpha.comOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) CEO Sells $23,896.60 in StockOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT - Get Rating) CEO Roger Crystal sold 1,183 shares of the stock in a transaction on Monday, January 9th. The stock was sold at an average price of $20.20, for a total transaction of $23,896.60. Following the completion of the transaction, the chief executive officer now directly owns 76,697 shares in the company, valued at approximately $1,549,279.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.January 9, 2023 | marketbeat.comOPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant ...January 7, 2023 | businesswire.comOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Short Interest UpdateOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT - Get Rating) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 30,700 shares, an increase of 153.7% from the November 30th total of 12,100 shares. Based on an average daily trading volume, of 85,100 shares, the days-to-cover ratio is presently 0.4 days.December 28, 2022 | marketbeat.comOpiant Pharmaceuticals (NASDAQ:OPNT) Cut to "Market Perform" at Northland SecuritiesNorthland Securities lowered shares of Opiant Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Wednesday.November 23, 2022 | marketbeat.comOpiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid OverdoseNovember 22, 2022 | finance.yahoo.comOppenheimer Comments on Opiant Pharmaceuticals, Inc.'s FY2022 Earnings (NASDAQ:OPNT)Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT - Get Rating) - Investment analysts at Oppenheimer reduced their FY2022 earnings per share estimates for Opiant Pharmaceuticals in a report released on Monday, November 14th. Oppenheimer analyst L. Gershell now expects that the technology company will earNovember 17, 2022 | marketbeat.comOPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant PharmaceuticalsNovember 15, 2022 | benzinga.comEQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNTNovember 15, 2022 | benzinga.comShareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with IndiviorNovember 14, 2022 | benzinga.comOPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to ShareholdersNovember 14, 2022 | benzinga.comIndivior To Buy Opiant For $145 Mln In CashNovember 14, 2022 | nasdaq.comOpiant surges 123% as Indivior set to acquire overdose therapy maker for $145MNovember 14, 2022 | seekingalpha.comOpiant Pharmaceuticals Shares Surge Premarket on Takeover by Indivior >OPNTNovember 14, 2022 | marketwatch.comIndivior PLC to Acquire Opiant PharmaceuticalsNovember 14, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Third Quarter 2022 Financial ResultsNovember 14, 2022 | finance.yahoo.comNarcan Owner Opiant to Be Acquired by Indivior for $145 MillionNovember 14, 2022 | finance.yahoo.comThe past five years for Opiant Pharmaceuticals (NASDAQ:OPNT) investors has not been profitableNovember 2, 2022 | finance.yahoo.comOpiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022October 27, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use DisorderOctober 6, 2022 | finance.yahoo.comINVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Opiant Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty ClaimsOctober 5, 2022 | marketwatch.comOpiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis SyndromeAugust 22, 2022 | finance.yahoo.comAnalysts Just Shaved Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts DramaticallyAugust 13, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate UpdateAugust 11, 2022 | finance.yahoo.comOpiant Pharma Secures Additional BARDA Funding For Opioid Overdose TreatmentAugust 9, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal NalmefeneAugust 8, 2022 | finance.yahoo.comOpiant Pharmaceuticals, Inc. (NASDAQ:OPNT) insiders sold US$871k worth of stock, possibly signalling a downtrendAugust 4, 2022 | nasdaq.comOpiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid OverdoseAugust 2, 2022 | finance.yahoo.comOpiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022August 1, 2022 | finance.yahoo.comA Look At The Fair Value Of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)June 9, 2022 | finance.yahoo.comOpiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal NalmefeneJune 8, 2022 | finance.yahoo.comOpiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid OverdoseJune 1, 2022 | finance.yahoo.comOpiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDTMay 20, 2022 | finance.yahoo.comOpiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call TranscriptMay 14, 2022 | seekingalpha.comTrading was temporarily halted for "OPNT" at 09:05 AM with a stated reason of "LULD pause."May 13, 2022 | marketbeat.comTrading was temporarily halted for "OPNT" at 09:05 AM with a stated reason of "LULD pause."May 13, 2022 | marketbeat.comOPNT: Positive Results for Pharmacodynamic Trial of OPNT003…May 12, 2022 | finance.yahoo.com Remove Ads Get Opiant Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter. Email Address OPNT Media Mentions By Week OPNT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPNT News Sentiment▼0.000.61▲Average Medical News Sentiment OPNT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPNT Articles This Week▼00▲OPNT Articles Average Week Remove Ads Get Opiant Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Capricor Therapeutics News Keros Therapeutics News Verve Therapeutics News Zevra Therapeutics News CorMedix News ORIC Pharmaceuticals News ABIVAX Société Anonyme News SIGA Technologies News Erasca News Altimmune News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPNT) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opiant Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opiant Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OPNT Stock Free OPNT Stock Alerts